Randomised clinical trial: macrogol/PEG 3350+electrolytes versus prucalopride in the treatment of chronic constipation ‐ a comparison in a controlled environment
Authors:
- 11 March 2013
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 37 (9) , 876-886
Abstract
Summary: Background: Constipation is a common condition for which PEG 3350 is an established treatment and prucalopride has recently been approved for this indication.Aim: To compare the efficacy, safety and impact on quality of life (QoL) of PEG 3350 plus electrolytes (PEG 3350+E) vs. prucalopride in females with chronic constipation (CC) in whom laxatives have previously failed to provide adequate relief.Methods: In this single‐centre, randomised, double‐blind, double‐dummy study, patients with CC [N = 120) or 1–2 mg prucalopride (N = 120) daily for 28 days following a 14‐day run‐in period. The primary endpoint was the proportion of patients having ≥3 SCBMs during the last treatment week.Results: Non‐inferiority of PEG 3350+E to prucalopride was demonstrated in the per‐protocol population [difference, 10.1% (66.67% vs. 56.52%), 97.5% lower confidence interval (CI) −2.7%, above the preset margin of −20%] and approached superiority in the modified intent‐to‐treat population (difference, 9.8%, 97.5% lower CI, −3.1%). Statistically significant differences in favour of PEG 3350+E were observed for most secondary variables (bowel movements, stool weight, consistency, time to next SCBM, patient perception of straining and completeness of defecation). Colonic transit time was dramatically reduced in both arms. Both treatments were well tolerated.Conclusion: PEG 3350+E was at least as effective as and generally better tolerated than prucalopride as a treatment for chronic constipation in this study population (NCT01251822; http://www.clinicaltrials.gov).Keywords
This publication has 34 references indexed in Scilit:
- Prucalopride: safety, efficacy and potential applicationsTherapeutic Advances in Gastroenterology, 2011
- Chronic Constipation: An Evidence-Based ReviewThe Journal of the American Board of Family Medicine, 2011
- Diagnosis and treatment of chronic constipation - a European perspectiveNeurogastroenterology & Motility, 2011
- Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12‐week, randomized, double‐blind, placebo‐controlled studyAlimentary Pharmacology & Therapeutics, 2008
- Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxativesGut, 2008
- Epidemiology of constipation in Europe and Oceania: a systematic reviewBMC Gastroenterology, 2008
- Effects of lactulose and polyethylene glycol on colonic transitAlimentary Pharmacology & Therapeutics, 2005
- The Health-Related Quality of Life and Economic Burden of ConstipationPharmacoEconomics, 2005
- Long term efficacy, safety, and tolerabilitity of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipationGut, 2000
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990